Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jordon3on Dec 19, 2017 2:20pm
71 Views
Post# 27188967

RE:RE:Outlook 2018---Full NASDAQ listing

RE:RE:Outlook 2018---Full NASDAQ listingThanks Kmuha....not sure if it's $1 or $2.
I don't know much about roll backs( reverse splits) and the consequences. Only from my observation the shareholders usually gets screwed.....especially longs.

Purely from a hypothetical standpoint
Say a shareholder has 1 million shares....only to be told there is going to be a 1:10 split.....in order to raise the price/share up high enough to meet the NASDAQ requirements.
This would leave the shareholder with 100,000 shares

Assuming again for a purely hypothetical discussion, the ProMis stock reaches $5 BEFORE the reverse split....that leave the shareholder with 5 million...............post reverse split it would be 500,000 bucks.   
Now for interest sake, say after the reverse spit the ProMis stock hits $30 buck.....this equates to only 3 million as opposed to the pre split of 5 million.

In fact the Promis stock would have to hit $50 dollars / share in order to be on par with the 1 million shares @ $5. 

 
If as it seems, ProMis has the goods...in my mind this reverse split is NOT in shareholders best interests from certain perspectives.  I have never seen it work that great for shareholders and as I said especially longs
I want to reiterate I don't know a lot about the advantages of consolidation.

Appreciate any feed back. 
Thanks
J

Bullboard Posts